24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Diabetes
Resources
Basic InformationLatest News
Diabetes Treatment Failure May Actually Be NonadherenceArtificial Intelligence Can Detect Diabetic RetinopathyMore Than 1 in 10 Patients May Be Overtreated for DiabetesPioglitazone Has Limited Effect in Lipoatrophic DiabetesFracture Risk Higher for Seniors With DiabetesCGM Use in Pregnancy Improves Neonatal OutcomesClosed-Loop Control Benefits T1DM in Prolonged Winter SportHeath Tip: Dining Out If You Have DiabetesExenatide Doesn't Up Cardiovascular Risk in T2DMIncreasing Salt Intake Tied to Diabetes RiskSotagliflozin Linked to Improved Glycemic Control in T1DMGreater Awareness Needed for Potential of T2DM RemissionCan Coffee or Tea Extend Survival With Diabetes?Could Artificial Sweeteners Raise Your Diabetes Risk?Could Swine Flu Be Linked to Type 1 Diabetes?'Upside' to Diabetes Really Isn'tLifestyle Tips for Better Diabetes ControlDiabetes Threatens Kidneys, Vision of Millions of Americans2017 Standards of Medical Care in Diabetes ReleasedBiomarkers Can Predict Rapid Drop in Renal Function in T2DMMany Teens With Type 1 Diabetes Report Disordered EatingCognitive Test Predicts Elderly Insulin Injection SuccessHigher Event Rate of T2DM in Polycystic Ovary SyndromeNovel Genetic Variant in IGF2 Linked to Reduced T2DM RiskFatty Acid Remodeling Seen in T2DM Remission Post Bariatric SxDiacerein Reduces Mean Hemoglobin A1c Levels in T2DMHealth Tip: Risk Factors for PrediabetesTablet Use Encourages Patients to Explore Diabetes RiskOnce-Yearly Counseling Tied to More Physical Activity in T2DMIn T2D, Glycemic Control Up With Continuous Glucose MonitoringSecure Messaging Linked to Better Diabetes ManagementStudies Often Fail to Include Info on T2DM Medication AdherenceIntensive Blood Pressure Tx Aids Those With PrediabetesLifestyle Intervention Only Offers Modest Benefit in Type 2 DiabetesSleep Duration Inversely Linked to Risk Markers of T2DM in KidsCould Big Lifestyle Changes Be Key to Managing Type 2 Diabetes?Variation in Participation in Diabetes Self-Management ClassTeam-Based Online Game May Improve Glycemic Control in T2DArtificial Sweeteners Trick the Brain: StudyCharacteristics of Diabetes in Infancy ExploredImmunotherapy Shown Safe in Type 1 Diabetes Clinical TrialOnline Game Helps Those With Diabetes Control Blood SugarHeart Health Ignored by Many With Type 2 DiabetesMortality Down Only for Gastric Bypass Patients With DiabetesInstagram Shows How Diabetics Really Wear a Glucose MonitorWhat Diabetics Need to Know About Over-the-Counter MedsEngineered Skin Cells Control Type 2 Diabetes in Mice: StudySimilar Defects ID'd for T2DM, Chronic Pancreatitis and DiabetesDiabetes Symptoms Appear to Spread Via Prion-Like MechanismPoor Adherence to Self-Monitoring of Glucose in GDM
Links
Related Topics

Medical Disorders

RUNX1 May Play Role in Proliferative Diabetic Retinopathy


HealthDay News
Updated: Apr 17th 2017

new article illustration

MONDAY, April 17, 2017 (HealthDay News) -- The Runt-related transcription factor 1 (RUNX1) gene may play a role in human proliferative diabetic retinopathy (PDR), and upregulation may be a marker of aberrant retinal angiogenesis, according to a study published online April 11 in Diabetes.

Noting that PDR affects those with type 1 and 2 diabetes, and is a common cause of blindness in the developed world, Jonathan D. Lam, M.D., from the Schepens Eye Research Institute in Boston, and colleagues examined the role of RUNX1 in PDR.

The researchers identified RUNX1 as a gene that was upregulated in CD31+ vascular endothelial cells obtained via transcriptomic analysis from human PDR fibrovascular membranes (FVM). Increased RUNX1 RNA and protein expression were seen in response to high glucose in in-vitro studies using human retinal microvascular endothelial cells (HRMECs); HRMEC migration, proliferation, and tube formation were reduced with RUNX1 inhibition. Using immunohistochemical staining for RUNX1, reactivity was seen in vessels of patient-derived FVM and angiogenic tufts in the retina of mice with oxygen-induced retinopathy. Use of the Ro5-3335 small molecule to inhibit RUNX1 activity resulted in significant reduction of neovascular tufts in oxygen-induced retinopathy.

"These findings, including the high glucose-dependent expression of RUNX1, identify a novel pathway of potential therapeutic interest, and implicate RUNX1 in aberrant angiogenesis in multiple conditions," the authors write.

Several authors have filed a provisional patent application on RUNX1 regulation for the treatment of aberrant angiogenesis and proliferative diabetic retinopathy.

Abstract/Full Text (subscription or payment may be required)